Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Research output: Contribution to journalArticle

Abstract

Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680.

Details

Authors
  • Christian H. Geisler
  • Arne Kolstad
  • Anna Laurell
  • Riikka Raty
  • Niels S. Andersen
  • Lone B. Pedersen
  • Marie Nordstrom
  • Eva Kimby
  • Hans Bentzen
  • Outi Kuittinen
  • Grete F. Lauritzsen
  • Herman Nilsson-Ehle
  • Elisabeth Ralfkiaer
  • Mats Ehinger
  • Christer Sundstrom
  • Jan Delabie
  • Marja-Liisa Karjalainen-Lindsberg
  • Peter Brown
  • Erkki Elonen
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology

Keywords

  • mantle cell lymphoma, autologous stem cell transplant, high-dose AraC, rituximab, pre-emptive therapy
Original languageEnglish
Pages (from-to)355-362
JournalBritish Journal of Haematology
Volume158
Issue number3
Publication statusPublished - 2012
Publication categoryResearch
Peer-reviewedYes